Company intelligence / Profile preview

Olympus Biotech

Hopkinton, Massachusetts, United Statesolympusbiotech.com ↗

Ownership: Private
Employees: ~23
Development stage: Other

Overview

Olympus Biotech focused on regenerative medicines to improve patient quality of life. Its key asset was Osteogenic Protein‑1 (OP‑1), acquired from Stryker Biotech in 2011. The company aimed to develop and distribute therapies stimulating tissue regeneration but discontinued its US biotechnology operations in 2014[6].

Therapeutic areas: Rheumatology
Modalities: Regenerative medicineCell therapyGene therapyTissue engineering
Industry: Biotech

Beyond the preview

Go deeper on Olympus Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olympus Biotech.